{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:32:13Z","timestamp":1792654333069,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jtos.2019.02.012","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T02:05:40Z","timestamp":1551665140000},"page":"412-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review"],"prefix":"10.1016","volume":"17","author":[{"given":"Edward J.","family":"Holland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-7158","authenticated-orcid":false,"given":"Mahshad","family":"Darvish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2937-1457","authenticated-orcid":false,"given":"Kelly K.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Karpecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2019.02.012_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib2","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1167\/iovs.11-9094","article-title":"Assessment of vision-related quality of life in dry eye patients","volume":"53","author":"Li","year":"2012","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib5","series-title":"Dry eye: a practical approach, essentials in Ophthalmology","article-title":"The epidemiology of dry eye disease","author":"Stapleton","year":"2015"},{"key":"10.1016\/j.jtos.2019.02.012_bib6","series-title":"USFDA approval of CEQUA","author":"Pharmaceuticals","year":"2018"},{"key":"10.1016\/j.jtos.2019.02.012_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/13543784.2016.1249564","article-title":"Investigational drugs in dry eye disease","volume":"25","author":"Nebbioso","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jtos.2019.02.012_bib8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: a systematic review","volume":"9","author":"Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2019.02.012_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1542-0124(12)70004-6","article-title":"Challenges and pitfalls in clinical trials of treatments for dry eye","volume":"1","author":"Foulks","year":"2003","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib11","series-title":"Preferred Practice Pattern\u00ae guidelines. Dry eye syndrome","author":"American Academy of Ophthalmology Cornea\/External Disease Panel","year":"2013"},{"key":"10.1016\/j.jtos.2019.02.012_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.02.012_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.2009.0091","article-title":"Topical cyclosporine 0.05% for the prevention of dry eye disease progression","volume":"26","author":"Rao","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1542-0124(12)70083-6","article-title":"Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib16","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/ICO.0b013e31823cc098","article-title":"A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction","volume":"31","author":"Prabhasawat","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2019.02.012_bib17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/bjo.2008.150011","article-title":"A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome","volume":"94","author":"Baiza-Duran","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.02.012_bib22","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.02.012_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.02.012_bib24","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2019.02.012_bib25","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","article-title":"A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients","volume":"96","author":"Takamura","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib26","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","article-title":"Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial","volume":"119","author":"Matsumoto","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.02.012_bib27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","article-title":"A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore","volume":"99","author":"Gong","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib28","doi-asserted-by":"crossref","first-page":"20855","DOI":"10.1038\/srep20855","article-title":"Randomized, multicenter, double-blind study of the safety and efficacy of 1% D-3-Hydroxybutyrate eye drops for dry eye disease","volume":"6","author":"Kawakita","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtos.2019.02.012_bib29","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s12325-015-0273-6","article-title":"Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of Visomitin eye drops in patients with dry eye syndrome","volume":"32","author":"Brzheskiy","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12325-015-0274-5","article-title":"SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model","volume":"33","author":"Petrov","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib31","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2147\/DDDT.S137825","article-title":"Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial","volume":"11","author":"Toshida","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib32","first-page":"181","article-title":"Definition and diagnosis of dry eye 2006","volume":"4","author":"Shimazaki","year":"2007","journal-title":"J Eye"},{"key":"10.1016\/j.jtos.2019.02.012_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtos.2016.09.003","article-title":"New perspectives on dry eye definition and diagnosis: a consensus report by the Asia dry eye society","volume":"15","author":"Tsubota","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","article-title":"Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial","volume":"131","author":"Amparo","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ICL.0000000000000276","article-title":"Multicenter study of a novel topical interleukin-1 receptor inhibitor, isunakinra, in subjects with moderate to severe dry eye disease","volume":"43","author":"Goldstein","year":"2017","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2019.02.012_bib36","first-page":"877","article-title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model","volume":"9","author":"Sosne","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib37","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3760\/cma.j.issn.0366-6999.20140048","article-title":"Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial","volume":"127","author":"Chen","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jtos.2019.02.012_bib38","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/OPTH.S44688","article-title":"Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye","volume":"7","author":"Meerovitch","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib39","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.02.012_bib40","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.02.012_bib41","series-title":"US prescribing information","author":"Restasis","year":"2017"},{"key":"10.1016\/j.jtos.2019.02.012_bib42","author":"US Food and Drug Administration"},{"key":"10.1016\/j.jtos.2019.02.012_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jtos.2019.02.012_bib44","author":"European Medicines Agency, Ikervis summary"},{"key":"10.1016\/j.jtos.2019.02.012_bib45","first-page":"2283","article-title":"Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease","volume":"42","author":"Solomon","year":"2001","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jop.2006.108","article-title":"Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery","volume":"23","author":"Akyol-Salman","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib47","series-title":"Xiidra prescribing","author":"Shire","year":"2018"},{"key":"10.1016\/j.jtos.2019.02.012_bib48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","article-title":"Lifitegrast, a novel integrin antagonist for treatment of dry eye disease","volume":"14","author":"Perez","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib49","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1586\/1744666X.2014.944163","article-title":"Mucosal environmental sensors in the pathogenesis of dry eye","volume":"10","author":"Pflugfelder","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jtos.2019.02.012_bib50","first-page":"1004","article-title":"Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome","volume":"43","author":"Argueso","year":"2002","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib51","first-page":"2602","article-title":"Alteration of mucin in human conjunctival epithelia in dry eye","volume":"39","author":"Danjo","year":"1998","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib52","first-page":"96","article-title":"Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model","volume":"42","author":"Fujihara","year":"2001","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/10807680260218524","article-title":"INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model","volume":"18","author":"Fujihara","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib54","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","article-title":"Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model","volume":"23","author":"Urashima","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2019.02.012_bib55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2011.0142","article-title":"Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells","volume":"28","author":"Takeji","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib56","series-title":"Otsuka pharmaceutical Co. Press release","author":"Otsuka Pharmaceutical Co L","year":"2012"},{"key":"10.1016\/j.jtos.2019.02.012_bib57","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.exer.2011.06.014","article-title":"An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye","volume":"93","author":"Jain","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2019.02.012_bib58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3177\/jnsv.58.223","article-title":"The effects of vitamin A compounds on hyaluronic acid released from cultured rabbit corneal epithelial cells and keratocytes","volume":"58","author":"Toshida","year":"2012","journal-title":"J Nutr Sci Vitaminol"},{"key":"10.1016\/j.jtos.2019.02.012_bib59","first-page":"580","article-title":"[Effect of vitamin A palmitate on the synthesis of mucins in cultured conjunctiva]","volume":"103","author":"Kubo","year":"1999","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jtos.2019.02.012_bib60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14712598.2012.634793","article-title":"Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications","volume":"12","author":"Goldstein","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtos.2019.02.012_bib61","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1167\/iovs.15-16890","article-title":"Primary mechanisms of thymosin beta4 repair activity in dry eye disorders and other tissue injuries","volume":"56","author":"Sosne","year":"2015","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2012.06682.x","article-title":"Thymosin beta4: a potential novel dry eye therapy","volume":"1270","author":"Sosne","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib63","series-title":"Inc. RegeneRx announces outcome of FDA discussions for development of RGN-259 for drye eye syndrome","author":"RegeneRx Biopharmaceuticals","year":"2018"},{"key":"10.1016\/j.jtos.2019.02.012_bib64","doi-asserted-by":"crossref","first-page":"8703645","DOI":"10.1155\/2016\/8703645","article-title":"Efficacy of mitochondrial antioxidant plastoquinonyl-decyl-triphenylphosphonium bromide (SkQ1) in the rat model of autoimmune arthritis","volume":"2016","author":"Andreev-Andrievskiy","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jtos.2019.02.012_bib65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1152\/physrev.1980.60.1.143","article-title":"Physiological roles of ketone bodies as substrates and signals in mammalian tissues","volume":"60","author":"Robinson","year":"1980","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jtos.2019.02.012_bib66","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1073\/pnas.97.10.5440","article-title":"D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease","volume":"97","author":"Kashiwaya","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtos.2019.02.012_bib67","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1167\/iovs.04-1344","article-title":"D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board","volume":"46","author":"Nakamura","year":"2005","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib68","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1167\/iovs.03-0198","article-title":"Protective effect of D-beta-hydroxybutyrate on corneal epithelia in dry eye conditions through suppression of apoptosis","volume":"44","author":"Nakamura","year":"2003","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.02.012_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/bmj.321.7256.255","article-title":"Which clinical studies provide the best evidence? The best RCT still trumps the best observational study","volume":"321","author":"Barton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2019.02.012_bib70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtos.2014.05.001","article-title":"Why aren't there more pharmacotherapies for dry eye?","volume":"12","author":"Novack","year":"2014","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib71","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jtos.2017.05.009","article-title":"TFOS DEWS II clinical trial design report","volume":"15","author":"Novack","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2019.02.012_bib73","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/jamaophthalmol.2013.2385","article-title":"Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface","volume":"131","author":"Schmidt","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jtos.2019.02.012_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jtos.2016.08.004","article-title":"A two-week, randomized, double-masked study to evaluate safety and efficacy of lubricin (150 \u03bcg\/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed\u00ae) in patients with moderate dry eye disease","volume":"15","author":"Lambiase","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.02.012_bib75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtos.2013.02.002","article-title":"Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies","volume":"11","author":"Alves","year":"2013","journal-title":"Ocul Surf"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012418303136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012418303136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:37:30Z","timestamp":1761539850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012418303136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1542012418303136"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2019.02.012","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2019.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}